Hyperphosphorylation of tau protein in hippocampus of central insulin-resistant rats is associated with cognitive impairment

Cellular Physiology and Biochemistry

Volumn 32, Issue 5, 2013, Pages 1417-1425

  Peng, Dantao ^a,b,e   Pan, Xiuqing ^b   Cui, Ju ^c   Ren, Yueqin ^d   Zhang, Jiewen ^b,e  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^b First People's Hospital of Zhengzhou   (China)

^c BEIJING HOSPITAL   (China)

^d The Second Affiliated Hospital of Henan Traditional Chinese Medicine College   (China)

^e BEIJING HOSPITAL   (China)

Author keywords

Alzheimer's disease; Hyperphosphorylation; Insulin resistance; Streptozotocin; Tau protein

Indexed keywords

GLUCOSE; INSULIN; STREPTOZOCIN; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTRAL INSULIN RESISTANCE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DIET RESTRICTION; GLUCOSE BLOOD LEVEL; GLUCOSE INTAKE; HIPPOCAMPAL CA1 REGION; HYPERPHOSPHORYLATION; IMMUNOHISTOCHEMISTRY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LATENT PERIOD; LIPID DIET; MALE; MAZE TEST; MEMORY DISORDER; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OPTICAL DENSITY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DIET; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RAT; SPATIAL LEARNING; WESTERN BLOTTING; ANIMAL TISSUE; COGNITION ASSESSMENT; ESCAPE BEHAVIOR; LEARNING DISORDER; MACROPHAGE ACTIVATION; MEMORY; MICROGLIA; MORRIS WATER MAZE TEST; NEUROPATHOLOGY;

ANIMALIA; RATTUS;

ALZHEIMER DISEASE; ANIMALS; COGNITION; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; INSULIN RESISTANCE; MALE; MAZE LEARNING; MICROGLIA; PHOSPHORYLATION; RATS; RATS, WISTAR; STREPTOZOCIN; TAU PROTEINS;

EID: 84890743398     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000356579     Document Type: Article

References (33)

1. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI: Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986;83:4913-4917.
2. Glenner GG, Wong CW: Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 1984;120:885-890.
3. Glenner GG, Wong CW, Quaranta V, Eanes ED: The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Appl Pathol 1984;2:357-369.
4. Cummings JL, Cole G: Alzheimer disease. JAMA 2002;287:2335-2338.
5. Anderson RN, Smith BL: Deaths: leading causes for 2001. Natl Vital Stat Rep 2003;52:1-85.
6. Gong CX, Liu F, Grundke-Iqbal I, Iqbal K: Post-translational modifications of tau protein in Alzheimer's disease. J Neural Transm 2005;112:813-838.
7. Iqbal K, Alonso Adel C, Chen S, Chohan MO, El-Akkad E, Gong CX, Khatoon S, Li B, Liu F, Rahman A, Tanimukai H, Grundke-IqbaI I: Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 2005;1739:198-210.
8. Ott A, Stolk RP, Hofman A, van Harskamp F, Grobbee DE, Breteler MM: Association of diabetes mellitus and dementia: the Rotterdam Study. Diabetologia 1996;39:1392-1397.
9. Luchsinger JA, Tang MX, Shea S, Mayeux R: Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004;63:1187-1192.
10. Plastino M, Fava A, Pirritano D, Cotronei P, Sacco N, Sperlì T, Spanò A, Gallo D, Mungari P, Consoli D, Bosco D: Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. J Neurol Sci 2010;288:112-116.
11. Ramos-Rodriguez JJ, Ortiz O, Jimenez-Palomares M, Kay KR, Berrocoso E, Murillo-Carretero MI, Perdomo G, Spires-Jones T, Cozar-Castellano I, Lechuga-Sancho AM, Garcia-Alloza M: Differential central pathology and cognitive impairment in pre-diabetic and diabetic mice. Psychoneuroendocrinology 2013;38:2462-2475.
12. Ar'Rajab A, Ahren B: Long-term diabetogenic effect of streptozotocin in rats. Pancreas 1993;8:50-57.
13. Park SW, Choi SA, Yun JW, Choi JW: Alterations in pancreatic protein expression in STZ-induced diabetic rats and genetically diabetic mice in response to treatment with hypoglycemic dipeptide Cyclo (His-Pro). Cell Physiol Biochem 2012;29:603-616.
14. Begum N, Sussman KE, Draznin B: Differential effects of diabetes on adipocyte and liver phosphotyrosine and phosphoserine phosphatase activities. Diabetes 1991;40:1620-1629.
15. Sonkusare S, Srinivasan K, Kaul C, Ramarao P: Effect of donepezil and lercanidipine on memory impairment induced by intracerebroventricular streptozotocin in rats. Life Sci 2005;77:1-14.
16. Kosaraju J, Gali CC, Khatwal RB, Dubala A, Chinni S, Holsinger RM, Madhunapantula VS, Muthureddy Nataraj SK, Basavan D: Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease. Neuropharmacology 2013;72:291-300.
17. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM: Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis 2006;9:13-33.
18. Shoham S, Bejar C, Kovalev E, Weinstock M: Intracerebroventricular injection of streptozotocin causes neurotoxicity to myelin that contributes to spatial memory deficits in rats. Exp Neurol 2003;184:1043-1052.
19. Bao BM, Shu SY: Cerebral Stereotaxic Atlas of Rats. Beijing, People's Medical Publishing House, 1991, pp 12-18.
20. Hosker JP, Matthews DR, Rudenski AS, Burnett MA, Darling P, Bown EG, Turner RC: Continuous infusion of glucose with model assessment: measurement of insulin resistance and beta-cell function in man. Diabetologia 1985;28:401-411.
21. Morris R: Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984;11:47-60.
22. Kraegen EW, Clark PW, Jenkins AB, Daley EA, Chisholm DJ, Storlien LH: Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 1991;40:1397-1403.
23. Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, Muschner D, Thalheimer A, Türk A, Hoyer S, Zöchling R, Boissl KW, Jellinger K, Riederer P: Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 1998;105:423-438.
24. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE: Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012;122:1316-1338.
25. Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, Farhang-Fallah J, Dikkes P, Warot XM, Rio C, Corfas G, White MF: Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 2003;23:7084-7092.
26. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA: Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989;3:519-526.
27. Alonso AC, Grundke-Iqbal I, Iqbal K: Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 1996;2:783-787.
28. Mandelkow EM, Mandelkow E: Tau in Alzheimer's disease. Trends Cell Bio 1998;8:425-427.
29. Ballatore C, Lee VM, Trojanowski JQ: Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007;8:663-672.
30. Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribé E, Dalfó E, Avila J: Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2005;2:3-18.
31. Eldar-Finkelman H: Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med 2002;8:126-132.
32. Schechter R, Beju D, Miller KE: The effect of insulin deficiency on tau and neurofilament in the insulin knockout mouse. Biochem Biophys Res Commun 2005;334:979-986.
33. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX: O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci USA 2004;101:10804-10809.